Background: To date, published studies suggest that a significant proportion of patients with Psoriatic Arthritis (PsA) present asymptomatic sacroiliitis; that is to say, an inflammatory back pain (IBP) absence. This fact could result in the underdiagnosis of axial involvement in these patients (1). Objectives: To evaluate the prevalence of radiographic sacroiliitis in patients with PsA and to determine its association with clinical, analytical and demographic factors. Methods: A cross-sectional, observational, and unicentre study in which clinical, analytical and demographic data from 359 patients belonging to a PsA monographic consultation were analyzed. All patients met the CASPAR criteria. The presence of sacroiliitis in the sacroiliac x-ray image was used as a dependent variable, formerly evaluated by a trained Rheumatologist. Likewise, independent variables related to arthropathy, cutaneous involvement and sociodemographic characteristics of the patients were used as well. A descriptive analysis and two logistic regressions (univariate and multivariate), were performed to associate radiographic sacroiliitis to different covariates. Results: Out of the 359 patients, 214 (59.6%) were men with a mean time of PsA evolution of 10.05±11.6 years. The x-ray image performed showed sacroiliitis in 127 patients (35.4%). Univariate analysis showed that radiographic sacroiliitis is related (p<0.05) to gender (men), psoriasic paternal family history, IBP, positive HLA-B27 antigen and psoriatic cutaneous involvement greater than 25%. The multivariate analysis showed that radiographic sacroiliitis in these patients is predominantly associated to the presence of IBP, the positive HLA-B27 antigen and gender (men). However, sacroiliitis is not not associated to the onset age of PsA (p>0.05).
Conclusions:
The prevalence of radiographic sacroiliitis in our population is 35.4%, higher than in other series due to the fact that the sacroiliac x-ray images were performed on all patients, regardless of the clinic. The radiographic sacroiliitis in patients with PsA is related to the presence of IBP, HLA-B27 antigen and gender. However, the time of evolution of arthropathy and the onset age of PsA are not related to sacroiliac radiographic involvement. Background: Dactylitis and enthesitis, hallmark features of psoriatic arthritis (PsA), may be difficult to manage. PALACE 1, 2, and 3 compared the efficacy and safety of apremilast (APR) with placebo (PBO) in patients (pts) with active PsA despite prior conventional DMARDs and/or biologics. Objectives: Report the impact of long-term APR 30 mg BID (APR30) treatment on dactylitis and enthesitis in pts with active PsA. Methods: Pts were randomized (1:1:1) to PBO, APR30, or APR 20 mg BID (APR20) stratified by baseline (BL) DMARD use (yes/no). After the 24-wk PBOcontrolled phase, all pts received APR30 or APR20 and could enroll in long-term follow-up. Data for pts entering the study with pre-existing dactylitis or enthesitis were pooled across PALACE 1-3, as prespecified, to allow for robust analysis. Dactylitis count (number of digits [hands/feet] with dactylitis present [0=absence, 1=presence]; range: 0-20) was used to assess dactylitis improvement. Enthesitis was evaluated based on MASES (range: 0-13), indicating the number of painful entheses out of 13 enthesis sites. Wk 24 analyses used LOCF for missing values and data for early escape pts; Wks 52 and 156 used data as observed. Results: Among pts with dactylitis (n=610) or enthesitis (n=915) at BL and ≥1 post-BL value, BL mean dactylitis counts ranged from 3.2 to 3.4 and MASES ranged from 4.4 to 4.8. At Wk 24, mean change in dactylitis count was −1.8 (APR30) vs −1.3 (PBO) (P=0.0097); more APR30 pts achieved a dactylitis count of 0 vs PBO pts (Table) . Mean change in MASES was −1.3 (APR30) vs −0.9 (PBO) (P=0.0194); more APR30 pts achieved a MASES of 0 vs PBO pts. Significant effect on enthesitis was confirmed in the PSA-006 (ACTIVE) study of APR in pts with a maximum of 1 previous DMARD treatment, in which the Gladman Enthesitis Index was used, focusing on more peripheral sites of activity: significant effect for APR vs PBO was seen as early as Wk 2, and at Wk 24, mean changes were −1.5 vs −0.5 (P=0.0032, MMRM). Sustained improvements in dactylitis and enthesitis severity were seen in APR pts at Wk 156 in PALACE 1-3 (Table) : for dactylitis, 79.6% achieved a count of 0 and the mean percent change was −83.6%; for MASES, 55.0% of APR pts achieved a score of 0 and the mean percent change was −65.2%.
The majority of pts (63%) in PALACE 1-3 had active enthesitis and 42% had dactylitis at BL. APR30 demonstrated early and long-term benefit (up to 156 wks) in treating dactylitis and enthesitis, including resolution of BL disease in many pts. Disclosure of Interest: D. Gladman Grant/research support from: AbbVie,
